Skip to main content
OpenTrials
Completed

NCT Number: NCT04397588

Extracorporeal Membrane Oxygenation (ECMO) and Coronavirus Disease (COVID) 19

The role of ECMO in the treatment of patients with severe COVID-19 (Acute Respiratory Distress Syndrome (ARDS) and/or acute refractory heart failure) is not yet known. The present study will aim to report the results of the ECMO management of the most severe forms of COVID-19 through the first French ECMO registry.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

ARDS Related to Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 2 Acute Refractory Heart Failure Related to SARS-CoV 2 COVID-19 Cardiomyopathies Cardiovascular Diseases Coronaviridae Infections Coronavirus Infections Heart Diseases Heart Failure Infections Lung Diseases Myocarditis Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Severe Acute Respiratory Syndrome Virus Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Angers University Hospital, Angers, France

Loading trial locations.

About this study

The main objective of this study is to evaluate the hospital survival of COVID-19 patients supported by venovenous or venoarterial ECMO in a multicenter registry.

The secondary objectives are to describe the characteristics of COVID-19 patients who have received ECMO support, to identify the risk factors associated with hospital mortality, to analyze the outcomes after ECMO weaning including survival at day 28 and day 90, and to analyze the utility of a circulatory support mobile unit in a severe pandemic

Inclusions are both prospective and retrospective in order to collect data over the whole pandemic

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All COVID-19 patients, adults or children,
  • Tested positive by RT-PCR for SARS-CoV2 (nasopharyngeal swabs, sputum, endotracheal aspiration, bronchoalveolar lavage or stool sample) and / or with a diagnosis made on chest CT findings,
  • Supported by venovenous or venoarterial ECMO

Exclusion criteria

  • Temporary legally protected Adults over a set period or waiting for protection supervision, guardianship
  • Patients or proxies who express their opposition to study participation

Treatment and study plan

Primary outcomes

  1. Hospital mortality

    Time frame: up to 90 days

    Hospital mortality

Secondary outcomes

  1. Mortality Day 28

    Time frame: Day 28

    Mortality Day 28

  2. Mortality Day 90

    Time frame: Day 90

    Mortality Day 90

  3. Ventilator-free days

    Time frame: Day 28

    Ventilator-free days

  4. Intensive care unit-free days

    Time frame: Day 28

    ICU-free days

  5. Hospital-free days

    Time frame: Day 28

    Hospital-free days

Sponsors and collaborators

Lead sponsor

Rennes University Hospital

Other

Registry information

Official study title

Extracorporeal Membrane Oxygenation (ECMO) as a Therapeutic Option in Severe Form of COVID-19: a Nationwide Cohort Study

Acronym: ECMO-SARS

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
May 21, 2020
Registry last updated
Jun 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.